@article{CDT155349,
author = {Chien-Hung Chang and Ching-Chang Chen and Chun-Ting Chen and Mun-Chun Yeap and Shuo-Chi Chien and Yi-Ming Wu and Zhuo-Hao Liu},
title = {Drug-coated balloons (DCB) for symptomatic intracranial atherosclerotic stenosis: a systematic review and meta-analysis},
journal = {Cardiovascular Diagnosis and Therapy},
volume = {16},
number = {3},
year = {2026},
keywords = {},
abstract = {Background: Intracranial atherosclerosis is a major cause of ischemic stroke, with high restenosis rates following angioplasty and stenting. Drug-coated balloons (DCBs) offer a potential alternative by delivering antiproliferative drugs to reduce restenosis. This systematic review and meta-analysis aimed to evaluate the restenosis rate and effectiveness of DCBs in treating intracranial atherosclerosis.Methods: PubMed, EMBASE, and Cochrane CENTRAL were searched from inception to April 13, 2025 (date of search). Eligible studies included randomized trials, and prospective and retrospective cohort studies evaluating DCBs in patients with symptomatic intracranial atherosclerosis. The primary outcomes were restenosis rate and degree of stenosis post-DCB treatment. Pooled proportions and odds ratios (ORs) with 95% confidence interval (CI) were calculated. Heterogeneity was assessed using the I2 statistic, and risk of bias with the Newcastle-Ottawa Scale.Results: Twenty-six studies involving 1,489 patients were included. The pooled restenosis rate after DCB treatment was 11% (95% CI: 9–13%; I2=26.8%). The pooled mean degree of stenosis after treatment was 34.34% (95% CI: 29.85–38.84%; I2=93.9%). In comparative studies, DCB was associated with a significantly lower restenosis rate than non-DCB treatment (OR =0.26; 95% CI: 0.16–0.44; P},
issn = {2223-3660}, url = {https://cdt.amegroups.org/article/view/155349}
}